stars 1 stars 2 stars 3

Agrenvec is focused on development, manufacture and marketing, of products and services for the R&D and Industrial markets. Our Company owns a patented technology platform allowing us a high-throughput production of fully active recombinant proteins with complex 3D structure. Our proteins are 100% animal free and minimum purity of 97%. This technology is based on the use of vectors derived from plant viruses. Our production system, compared to transgenic plants, is more efficient and flexible, faster and cheaper. Its scaling up is easier and linear; we obtain from milligrams to kilograms of the protein of interest. Agrenvec has developed unique purification protocols that combined with our technology platform enable us to produce recombinant proteins very competitively. We have accumulated a deep know-how in industrial production of recombinant proteins and antibodies. After several years of experience we control the whole value chain, from the bench to the final product, thanks to our highly qualified team. Agrenvec is client-focused, so we adapt to our customer needs in all our projects. Some of our projects have been co-founded by the Spanish Ministry of Science, and other public organizations, such as Innovation Department of Madrid Regional Government, CDTI, ENISA, Genoma EspaƱa.

Agrenvec Questions

The Agrenvec annual revenue was $6.4 million in 2026.

Agrenvec is based in Tres Cantos, Madrid.

The NAICS codes for Agrenvec are [54, 54171, 5417, 541, 541713].

The SIC codes for Agrenvec are [873, 87].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users